Home > Publications database > The fentanyl-specific antibody FenAb024 can shield against carfentanil effects. > print

001     289319
005     20250826120019.0
024 7 _ |a 10.1016/j.toxlet.2024.03.008
|2 doi
024 7 _ |a pmid:38588756
|2 pmid
024 7 _ |a 0378-4274
|2 ISSN
024 7 _ |a 1879-3169
|2 ISSN
037 _ _ |a DKFZ-2024-00714
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Urban, Katharina
|b 0
245 _ _ |a The fentanyl-specific antibody FenAb024 can shield against carfentanil effects.
260 _ _ |a Amsterdam [u.a.]
|c 2024
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1713790231_13381
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:D150# / Volume 396, 15 May 2024, Pages 1-10
520 _ _ |a The surge in opioid-related deaths, driven predominantly by fentanyl and its synthetic derivatives, has become a critical public health concern, which is particularly evident in the United States. While the situation is less severe in Europe, the European Monitoring Centre for Drugs and Drug Addiction reports a rise in drug overdose deaths, with emerging concerns about the impact of fentanyl-related molecules. Synthetic opioids, initially designed for medical use, have infiltrated illicit markets due to their low production costs and high potency, with carfentanil posing additional threats, including potential chemical weaponization. Existing overdose mitigation heavily relies on naloxone, requiring timely intervention and caregiver presence, while therapeutic prevention strategies face many access challenges. To provide an additional treatment option, we propose the use of a fentanyl-specific monoclonal antibody (mAb), as a non-opioid method of prophylaxis against fentanyl and carfentanil. This mAb shows protection from opioid effects in a pre-clinical murine model. mAbs could emerge as a versatile countermeasure in civilian and biodefense settings, offering a novel approach to combat opioid-associated mortality.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Opioid crisis
|2 Other
650 _ 7 |a antibody-associated protection
|2 Other
650 _ 7 |a carfentanil
|2 Other
650 _ 7 |a fentanyl
|2 Other
650 _ 7 |a monoclonal antibodies
|2 Other
650 _ 7 |a passive immunization
|2 Other
700 1 _ |a Gkeka, Anastasia
|b 1
700 1 _ |a Chandra, Monica
|b 2
700 1 _ |a Greiner, Dennis
|b 3
700 1 _ |a Pollich, Selina
|b 4
700 1 _ |a Ruf, Sandra
|0 P:(DE-He78)987a16a93296d4a043a1b2337d224b53
|b 5
|u dkfz
700 1 _ |a Kelemen, Yosip
|b 6
700 1 _ |a Sundermann, Tom
|b 7
700 1 _ |a Pravetoni, Marco
|b 8
700 1 _ |a Baehr, Carly
|b 9
700 1 _ |a Stebbins, C Erec
|0 P:(DE-He78)3e1497ece09f8d2c69efc8b106a08f2b
|b 10
|u dkfz
700 1 _ |a Papavasiliou, F Nina
|0 P:(DE-He78)79dbda58d51b613a0a421f579d2dfed3
|b 11
|u dkfz
700 1 _ |a Verdi, Joseph Peter
|0 P:(DE-He78)e13953968ed53b7fcae1139ac9ea7583
|b 12
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.toxlet.2024.03.008
|g p. S0378427424000559
|0 PERI:(DE-600)1500784-4
|p 1-10
|t Toxicology letters
|v 396
|y 2024
|x 0378-4274
856 4 _ |u https://inrepo02.dkfz.de/record/289319/files/1-s2.0-S0378427424000559-main.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/289319/files/1-s2.0-S0378427424000559-main.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:289319
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)987a16a93296d4a043a1b2337d224b53
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)3e1497ece09f8d2c69efc8b106a08f2b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)79dbda58d51b613a0a421f579d2dfed3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)e13953968ed53b7fcae1139ac9ea7583
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-08-23
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-23
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-23
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b TOXICOL LETT : 2022
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-23
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-23
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-23
920 2 _ |0 I:(DE-He78)D150-20160331
|k D150
|l D150 Immundiversität
|x 0
920 1 _ |0 I:(DE-He78)D150-20160331
|k D150
|l D150 Immundiversität
|x 0
920 1 _ |0 I:(DE-He78)D160-20160331
|k D160
|l Strukturbiologie von Infektion und Immunität
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D150-20160331
980 _ _ |a I:(DE-He78)D160-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21